{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:54:41Z","timestamp":1791125681826,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,6,15]]},"abstract":"<jats:p> PURPOSE: Corticosteroids are widely used in the treatment of acute lymphoblastic leukemia (ALL). To determine the frequency of corticosteroid-associated bony morbidity in children with ALL, we retrospectively evaluated the incidence of fractures and osteonecrosis (ON) on two consecutive pediatric ALL protocols. <\/jats:p><jats:p> PATIENTS AND METHODS: One hundred seventy-six consecutive children were treated for ALL between 1987 and 1995 at the Dana-Farber Cancer Institute and Children\u2019s Hospital. Prednisone was used as the corticosteroid during postremission therapy from 1987 to 1991, and dexamethasone was used from 1991 to 1995. Medical records for all patients were reviewed to assess the occurrence of fractures and ON. <\/jats:p><jats:p> RESULTS: With a median follow-up of 7.6 years, the 5-year cumulative incidence (CI) \u00b1 SE of any bony morbidity for the 176 patients was 30% \u00b1 4%, with a 5-year CI of fractures of 28% \u00b1 3% and of ON of 7% \u00b1 2%. With multivariate analysis, independent predictors of bony morbidity included age 9 to 18 years at diagnosis (P &lt; .01), male sex (P &lt; .01), and treatment with dexamethasone (P = .01). Dexamethasone was associated with a higher risk of fractures (5-year CI, 36% \u00b1 5% v 20% \u00b1 4% with prednisone; P = .04), but not ON (P = .40). The 5-year event-free survival for the 176 patients was 79% \u00b1 3%. <\/jats:p><jats:p> CONCLUSION: Children treated for ALL had a high incidence of fractures and ON. Older children, boys, and patients receiving dexamethasone were at increased risk for the development of bony morbidity. Future studies should attempt to minimize corticosteroid-associated bony morbidity without compromising clinical efficacy. <\/jats:p>","DOI":"10.1200\/jco.2001.19.12.3066","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:20:33Z","timestamp":1487920833000},"page":"3066-3072","source":"Crossref","is-referenced-by-count":203,"title":["Bony Morbidity in Children Treated for Acute Lymphoblastic Leukemia"],"prefix":"10.1200","volume":"19","author":[{"given":"Adam J.","family":"Strauss","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, Massachusetts General Hospital; Quality Control Center and Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute; and Division of Hematology\/Oncology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce T.","family":"Su","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Massachusetts General Hospital; Quality Control Center and Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute; and Division of Hematology\/Oncology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M. Kimball","family":"Dalton","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Massachusetts General Hospital; Quality Control Center and Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute; and Division of Hematology\/Oncology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Massachusetts General Hospital; Quality Control Center and Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute; and Division of Hematology\/Oncology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Massachusetts General Hospital; Quality Control Center and Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute; and Division of Hematology\/Oncology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Massachusetts General Hospital; Quality Control Center and Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute; and Division of Hematology\/Oncology, Children\u2019s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-090439","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"R2-090439","unstructured":"Schrappe  M,   Reiter  A,   Ludwig  WD,  et al:  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy:  Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.   Blood 95:  3310,2000-3322,"},{"key":"R3-090439","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.411"},{"key":"R4-090439","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650111122"},{"key":"R5-090439","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199805000-00009"},{"key":"R6-090439","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199904010-00014"},{"key":"R7-090439","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690296"},{"key":"R8-090439","doi-asserted-by":"publisher","DOI":"10.1136\/adc.80.2.143"},{"key":"R9-090439","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900415)65:8<1717::AID-CNCR2820650809>3.0.CO;2-B"},{"key":"R10-090439","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(05)80026-5"},{"key":"R11-090439","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950210909"},{"key":"R12-090439","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(97)80253-X"},{"key":"R13-090439","doi-asserted-by":"publisher","DOI":"10.1097\/01241398-200005000-00012"},{"key":"R14-090439","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.18.3262"},{"key":"R15-090439","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199901)32:1<11::AID-MPO4>3.0.CO;2-F"},{"key":"R16-090439","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.2.202"},{"key":"R17-090439","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190411"},{"key":"R18-090439","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2370"},{"key":"R19-090439","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199608)27:2<114::AID-MPO8>3.0.CO;2-I"},{"key":"R20-090439","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401980"},{"key":"R23-090439","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"R24-090439","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"R25-090439","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R27-090439","doi-asserted-by":"crossref","unstructured":"Landin  LA:   Fracture patterns in children:  Analysis of 8,682 fractures with special reference to incidence, etiology and secular changes in a Swedish urban population 1950-1979.   Acta Orthop Scand Suppl 202:  1,1983-109,","DOI":"10.3109\/17453678309155630"},{"key":"R28-090439","doi-asserted-by":"publisher","DOI":"10.1097\/01241398-198611000-00003"},{"key":"R29-090439","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1"},{"key":"R30-090439","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200005000-00004"},{"key":"R31-090439","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.911"},{"key":"R32-090439","unstructured":"Bostrom  B,   Gaynon  PS,   Sather  H,  et al:  Dexamethasone decreases central nervous system relapse and improves event-free survival in lower risk acute lymphoblastic leukemia.  Proc Am Soc Clin Oncol 17:  527a,1998  (abstr)"},{"key":"R33-090439","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70349-7"},{"key":"R34-090439","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1570"},{"key":"R35-090439","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199806)30:6<347::AID-MPO8>3.0.CO;2-E"},{"key":"R36-090439","doi-asserted-by":"publisher","DOI":"10.1097\/00005131-199302000-00004"},{"key":"R37-090439","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708073370603"},{"key":"R38-090439","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390502"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.12.3066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:44:36Z","timestamp":1653515076000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.12.3066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,15]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,6,15]]}},"alternative-id":["10.1200\/JCO.2001.19.12.3066"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.12.3066","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6,15]]}}}